We Finally Have a Weapon Against the Deadliest Cancer

Kind: captions Language: en Pancreatic cancer isn't a silent disease that you can catch early. It's stealth. It slips past the body's early warning signs. So, by the time something feels wrong, it's often already advanced. Over the years, survival has barely moved. Only a handful of patients out of every 100 ever make it through. Statistically, it's like playing Russian roulette with five chambers loaded out of six. But, after decades of failure, researchers have started breaking through pancreatic cancer's defenses. They've turned it from untouchable into something they can go after. And what they've discovered inside that stealth system changes everything. Pancreatic cancer is one of the most lethal diseases around. While modern medicine has made huge headway combating viruses and improving cancer survival rates, pancreatic cancer has remained an unsolved mystery. A fortress that's been impossible for doctors to penetrate with drugs. Even with modern medical developments, the overall survival rate for pancreatic cancer is low, very low. Today, it sits at only 13%. It is the lowest of all major cancers. In rich countries, the average 5-year survival rate for all cancers diagnosed in 2017 was 70%. And it gets worse because most pancreatic cancers don't get identified until it's too late. They've already metastasized to stage four. In fact, over four out of five pancreatic cancers get diagnosed at this stage. The survival rate for metastatic pancreatic cancer in 5 years, only 3% of patients are still alive. What makes it so lethal? It's the way pancreatic cancer works. It's a perfect storm of location, immune response, and presentation. Pancreatic tumors rarely cause noticeable symptoms, partly because of their location deep inside the body. They don't become physically visible, and they don't cause symptoms a patient can feel until they've spread to other organs and parts of the body. There's no screening test to catch the disease early as it builds up quickly and quietly. Usually, patients only notice the first symptoms, jaundice and abdominal pain, once the cancer is already spread. By then, the chances of survival are next to nothing. Pancreatic cancer suppresses the body's early warning systems because of its own structure, making it virtually treatment proof until now. Doctors were always puzzled at the body's response to pancreatic cancer because in most patients, there was almost none. They couldn't figure out why patients' immune systems never seemed to come online. Cancer cells would grow and multiply throughout the body without T cells putting up any kind of fight to stop it. Then researchers discovered what was actually going on. Pancreatic tumors cloak themselves with glycoproteins to mimic healthy cells. This sugar coating signals to the immune system to stand down, allowing the tumor cells to hide in plain sight. The most common form of pancreatic cancer, PDAC, may trigger some kind of immune response, but the T cells still can't infiltrate the tumor. There's something in the design of pancreatic cancer cells that stops the one thing that could fight them in its tracks. But there's a new development on the horizon because the untreatable, undruggable code has just been broken. To outsmart pancreatic cancer, scientists had to find a way to permeate the concrete bunker the cancer creates, a bunker known as the desmoplastic stroma, a fortified wall scientists thought was almost impossible to break through. As pancreatic cancer grows, it hijacks the cells around it. The mutated cancer cells, in turn, damage the tissue around them. As a result, the body's wound healing mode is activated, creating scar tissue around the tumor. PDAC uses this tissue as a shield, called a stroma. It's much denser than the tissue that surrounds most other cancers. For some reason, PDAC creates an incredibly fibrous tissue barrier that stops most cancer treatments from ever reaching the cells they're supposed to fight. Besides working as the worst kinds of high security fence, the desmoplastic stroma creates another problem, internal fluid pressure. Tumor cells create a highly hydrophilic sugar that attracts and absorbs water, causing parts of the tumor to swell. But, the tumor can't drain or expand outwards because the dense stroma is blocking it. It is like filling a balloon with water inside of a concrete shell. There's nowhere for it to expand, resulting in internal pressure on the cells and blood vessels. Even if the doctors could find a way around the barrier, the pressure the stroma creates physically squeezes shut the blood vessels that would deliver the medicine. At that point, chemotherapy becomes a losing battle. Throwing drugs at a pancreatic tumor becomes akin to throwing spaghetti at a wall and expecting it to pass through. All of this made traditional therapies against pancreatic cancer painful and mostly useless. The medical world had to come up with something else, something better. Enter Neliridox. Traditional chemotherapy doesn't target cancer cells, it targets everything. Chemo is the equivalent of biological carpet bombing. Used against a disease it can't reach, it basically ends up killing a lot of functional parts of the body while leaving the pancreatic tumor untreated. One oncologist, Dr. Sameer Rechaudhuri, had said, "Even with our best chemotherapies, the average benefit is around 6 months, sometimes as little as weeks or months. It's barely enough time for families to grasp the situation." But, Neliridox uses a smarter approach, a targeted one. The drug uses the cancer's stealth against itself. It slips past healthy tissue, breaks through the tumor's defenses, and only releases its full payload once it's inside. A study called the NAPOLI-3 trial was conducted across 18 countries to see how effective the new medication was. 770 patients who had been diagnosed with metastatic pancreatic cancer, the deadliest kind, were selected to take part in the trial in 2020 and 2021. About half of them were given Neliridox, while the other half was given the normal first-line chemotherapy treatment for metastatic pancreatic cancer. Those who were given the standard chemotherapy treatment had a median survival rate of 9.2 months. Those who had been treated with an Nalerafox had an extended median survival rate of 11.1 months. While that may not seem like much to the average person, it is a major victory for oncology. That translates to a 20% improvement in survival for what was considered an almost certainly terminal disease. In the world of cancer, that is a generational leap forward. In addition, patients took Nalerafox for 6 weeks more on average than the standard chemotherapy treatment, which allowed the drug itself to be more effective. Due to these incredible results, the FDA made reviewing Nalerafox a top priority. In February 2024, the drug got official FDA approval, making it more easily accessible to patients who needed it, as well as possibly affordable. Though the FDA doesn't directly control what insurance can and can't cover, when a drug is FDA approved, it usually translates to being covered by Medicare and Medicaid. But Nalerafox is just step one, because once doctors got inside the tumor, they still had to deal with a dangerous enemy, one they couldn't possibly touch, a genetic villain that had made pancreatic cancer a death sentence for most. The structure of the mutation that caused the cancer itself. Approximately 90 to 95% of pancreatic cancers are driven by the KRAS mutation. Science had famously labeled it as untouchable for 40 years. The KRAS gene works like an on-off switch controlling how cells grow in the body. In most pancreatic cancers, the KRAS had somehow been flipped into the on position and becomes permanently stuck there. Scientists had figured out the exact mutation they needed to target. The problem? They had no way of going about it. Drugs usually work by latching onto a protein surface, but the KRAS mutation was incredibly smooth, so smooth scientists called it the greased ball. Nothing could latch on. Medicines couldn't bind to it, and as long as they couldn't bind to it, they couldn't work against it. Until scientists realized they were going about it all wrong. Billions were spent trying to find a way to grip the surface of the protein. Decades of experimental drugs and clinical trials turned out to be complete flops. But there was a hidden flaw in the armor all along. One that could be used to go after the heart of the tumor. Because the protein may not have had a crevice for drugs to latch onto, but scientists realized that using the right methods, they could force one to open. The problem was never what it appeared to be in the first place. The funding for the war on cancer hadn't been wasted. Scientists put a lot of effort into discovering exactly the chemicals needed to kill the cancer cells. The only problem was that the KRAS protein seemingly had no pocket for the drugs to sit in to deliver the fatal chemical dose. In 2013, Kevin Shokat, a biochemist at the University of California, San Francisco, focused on a specific KRAS mutation called G12C. In simple terms, this mutation turns glycine into a highly reactive residue. Scientists designed a bunch of molecules that would glue themselves onto it. And when they did, something interesting happened. The gluing action forced the protein to shift, revealing a small hidden cavity within it. Scientists called this discovery the switch two pocket. Shokat's breakthrough only applied to a tiny fraction of pancreatic cancers, less than 1%. But it proved something many researchers had doubted for decades. KRAS could be targeted. Finding the right chemicals that would take advantage of this back door for most other types of pancreatic cancer took much longer. Ones that could be used not to attack the protein, but to take it offline altogether. Over 480 potential compounds were screened for bonding to the switch two pocket until they found the chemicals that would turn the KRAS switch back to the off position, forever. Scientists had unlocked the perfect drug delivery system. Now they just needed to develop a highly specific weapon to exploit it. But there was a problem. The compounds were almost too precise. They only worked against that specific mutation. Change the mutation and the drugs lost their target, becoming virtually useless against the cancer. After years of research and experimentation, it appears scientists have the answer they want, their own personal assassin, lethal against the world's deadliest cancer, the RAS on RAS inhibitor. And it could be the holy grail of oncology. Researchers had already come up with some targeted KRAS G12C inhibitors. But they were a little too targeted. They weren't as effective against pancreatic tumors as doctors would like them to be. If the protein mutated further or became drug resistant, these drugs effectiveness went down to almost nothing. The RAS on RAS inhibitor is more broad spectrum and it shows potential to overcome drug resistance to first generation inhibitors. The drug works by recruiting a helper molecule called cyclophilin A. Acting like a kind of molecular glue, it creates a connection that lets the drug lock onto the KRAS and shut down the signals driving the cancer's growth. So, the drug rips through the body, finds the mutated KRAS proteins, and latches onto them like a magnet. Where chemotherapy is a full-on carpet bombing, the RAS on RAS inhibitor functions as a targeted assassination. The results were outstanding. In a series of drug trials, 500 patients were selected to either receive chemotherapy or treatment with the RAS on RAS inhibitor. Almost 92% of them had KRAS G12 mutations. The average survival rate for chemotherapy was 6.7 months. For those treated with the RAS on RAS inhibitor, it increased to 13.2 months. Individual patient reports also showed that for most, the RAS on RAS inhibitor was much less toxic than chemotherapy. Patients experienced fewer and less severe side effects overall, and way fewer decided to stop the treatment because of that. It only gets better because KRAS mutations don't just drive pancreatic cancer, they trigger a whole lot of tumors, including lung, colorectal, ovarian, endometrial, and some of the other most common and deadly cancers around. Over 5.1 million people are diagnosed with one of those four cancers every year, in addition to the over 500,000 people that will receive a diagnosis of pancreatic cancer. A drug that went after the KRAS mutations that caused the cancer could give a whole new hope and be the literal difference between life and death for 5.6 million people annually. In fact, just the lung, pancreatic, and colon cancers alone are the three leading causes of cancer deaths. Cracking the KRAS G12D mystery doesn't just provide hope for pancreatic cancer patients, but for all patients suffering from KRAS-driven cancers. While this new miracle drug starts taking out current tumor targets, there's an even brighter future on the horizon. Scientists are on the brink of another incredible development, a technology that doesn't just target cancer, but ensures that the tumor never returns, a cancer vaccine. While Deraxol Rassiv is a near miraculous development, it's not the end of the story for pancreatic cancer patients. Because for most people, Deraxol Rassiv stops working after a while. Their tumor becomes drug resistant. Despite an extended lifespan, they are left once again facing their worst fear, the return of their cancer. One company is using mRNA technology, like the kind used in the vaccine that ended the COVID-19 pandemic, to change the narrative. Their hope is to use modern medicine not just to treat pancreatic cancer, but to stop it from ever coming back again. The BioNTech customizable mRNA vaccine is currently in its phase one trial. So far, the results look promising. The vaccine is custom-made for each patient based on their unique tumor DNA to better target the cancerous cells it needs to eradicate, which differ from patient to patient. In the BioNTech trial, vaccines were given to 16 patients after pancreatic cancer surgery. The treatment was paired with chemotherapy and immunotherapy drugs. In half of the patients, the vaccine activated tumor-specific immune cells. The mRNA shots specifically trained these soldier cells to recognize the tumor's unique signature and wipe out the cancerous cells. They teamed up with the body's own immune system to train it to identify and fight the pancreatic invader. And how effective is this current search and destroy vaccine for pancreatic cancer? Of the eight patients whose immune systems the vaccine activated, seven of them were still alive four to six years after surgery. That's an almost 90% survival rate, much higher than the 13% currently attributed to pancreatic cancer patients. Oncologists were stunned at the results. One doctor at Memorial Sloan Kettering Cancer Center said of the new vaccine, "It has the potential to make a difference for one of the deadliest cancers." Researchers still need to figure out why some patients' immune systems respond to the vaccine while others don't. Even for those who might respond well to the vaccine, there is a huge question of if they can get it in the first place because the cost of survival is shockingly high. Nalira Fox directs on RAS and personalized mRNA vaccines. All of them represent giant technological, scientific, and medical leaps forward. Unfortunately, all of them are currently out of reach for all but the wealthiest of patients. Each of these drugs costs tens of thousands of dollars per cycle, and the cycles needed to keep someone in remission over a lifetime can add up to astronomical costs. Nalira Fox costs an average of $7,800 per cycle. For the multiple cycles of treatment required, this can easily add up to between $150,000 to $200,000 in lifetime costs. That's enough to cover a four-year degree at a private university or even a starter home in a cheaper area. Paying it for one drug alone would throw most people into bankruptcy. And in combination with the other drugs on the list, that would be prohibitively expensive. Deraxonal RAS is not yet commercially available, but an analysis of Revolution Medicine's potential profits revealed how much the company expects to charge patients for it. A monthly course would be priced between 30,500 and 37,300. The per-patient revenue adds up to an average of $250,000. Taking these two drugs together would already put the average pancreatic cancer patient half a million in the hole. That's before they've even considered a custom-made mRNA vaccine. The cost for that, BioNTech has stated, after years of work, they can probably get it down to under an eye-watering $100,000 per dose. Will access to potentially life-saving medicine be given to all patients, or will it represent yet another health care divide? One where the elite get the most effective drugs and best chances of survival, while everyone else defaults to paying exorbitant amounts for chemo and just hoping for the best. The good news is the FDA has approved expanded access to Krazati based on its early promising results. And now that researchers have shown that KRAS can be beaten, pharmaceutical companies are racing to develop their own drugs to exploit the crack in its armor. As of June 2026, Johnson & Johnson has spent $1 billion to enter the race for KRAS-related cancer treatments. Theoretically, competition between the major pharmaceutical companies should drive drug prices down. But, given the fact that in countries like the US, many drugs remain distressingly out of reach for the average citizen due to cost, even with competition in the mix, the political and social reality of these medical leaps forward in the future remains to be seen. But, does this all mean that we're at the end of the cancer death sentence? One thing is certain, we've entered a new scientific reality, a god mode era of oncology, one in which no mutation is off limits, where undruggable conditions don't make diseases untreatable, they just present another challenge to be solved. The new methods developed to treat KRAS mutations can be applied to a whole lot of formally undefeatable mutations and proteins. The only thing that is doomed is pancreatic cancer's horrific 13% survival rates. Based on the trials, patients treated with these new medical miracles had their life spans almost double after being diagnosed with pancreatic cancer. Even patients with metastatic pancreatic cancer saw their risk of death reduced by 60%. Better yet, the actual quality of patients' lives went up as well. The milder side effects of Droxid Neracept meant these patients gained more extra months. They gained quality of life and more time with loved ones. And the only thing they needed to do was take three pills once a day. Families that in the past only wished for at best a few more months with loved ones through painful excruciating rounds of chemotherapy now have new hope. The hope is that they could get anywhere from over a year to several years with their relatives after a pancreatic cancer diagnosis. Even the hope that one day their loved one could be completely cancer-free. The medical community has come together to quite literally give people new life. And the dream is that these breakthroughs won't stop at pancreatic cancer. Cracking the un-drugable code could be the first step in treating some of the deadliest cancers the world has ever seen. The new medicines being developed today could save enough people to fill up an entire major city every single year. And who knows what other miracles the future of medicine could bring. Breakthroughs like this can buy time, but they can't stop the inevitable. And those who see it every day have learned some surprising lessons. Find out more in what doctors wish their patients knew about death or watch t